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Abstract
Background: Nor-BNI, GNTI and JDTic induce selective k opioid antagonism that is delayed and extremely prolonged, but
some other effects are of rapid onset and brief duration. The transient effects of these compounds differ, suggesting that
some of them may be mediated by other targets.
Results: In binding assays, the three antagonists showed no detectable affinity (Ki$10 mM) for most non-opioid receptors
and transporters (26 of 43 tested). There was no non-opioid target for which all three compounds shared detectable affinity,
or for which any two shared sub-micromolar affinity. All three compounds showed low nanomolar affinity for k opioid
receptors, with moderate selectivity over m and d (3 to 44-fold). Nor-BNI bound weakly to the a2C-adrenoceptor
(Ki = 630 nM). GNTI enhanced calcium mobilization by noradrenaline at the a1A-adrenoceptor (EC50 = 41 nM), but did not
activate the receptor, displace radioligands, or enhance PI hydrolysis. This suggests that it is a functionally-selective
allosteric enhancer. GNTI was also a weak M1 receptor antagonist (KB = 3.7 mM). JDTic bound to the noradrenaline
transporter (Ki = 54 nM), but only weakly inhibited transport (IC50 = 1.1 mM). JDTic also bound to the opioid-like receptor
NOP (Ki = 12 nM), but gave little antagonism even at 30 mM. All three compounds exhibited rapid permeation and active
efflux across Caco-2 cell monolayers.
Conclusions: Across 43 non-opioid CNS targets, only GNTI exhibited a potent functional effect (allosteric enhancement of
a1A-adrenoceptors). This may contribute to GNTI’s severe transient effects. Plasma concentrations of nor-BNI and GNTI may
be high enough to affect some peripheral non-opioid targets. Nonetheless, k opioid antagonism persists for weeks or
months after these transient effects dissipate. With an adequate pre-administration interval, our results therefore strengthen
the evidence that nor-BNI, GNTI and JDTic are highly selective k opioid antagonists.
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Introduction
Selective k (kappa) opioid antagonists may have therapeutic
potential against conditions such as depression and anxiety
disorders [1,2]. The best-established agents in this class, shown
in Figure 1, are nor-BNI, GNTI and JDTic. In vitro, these
compounds are potent and selective antagonists at the k opioid
receptor (k-OR), with much lower potency at m- (mu) and d- (delta)
OR [3]. They are therefore generally considered k-selective, but
little evidence is available on binding and activity at other
receptors, ion channels, transporters and enzymes.
Delayed, prolonged k opioid antagonism
The pharmacodynamics of these compounds in vivo differ
dramatically from other opioid antagonists. Attainment of
maximal k opioid antagonism may be delayed by hours or days,
compared to minutes for competitive antagonists like naloxone [4].
Duration of action is also extremely long; while competitive
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antagonists are typically effective for only hours or at most days, k
antagonism can persist for weeks or months after nor-BNI, GNTI
or JDTic [4]. To account for this abnormal timecourse, it was long
presumed that these compounds were slowly absorbed and
eliminated. Recently, studies have suggested instead that nor-
BNI, GNTI and JDTic activate the enzyme c-Jun N-terminal
kinase 1 (JNK1, MAPK8), causing desensitization of k-OR that
persists long after the compounds are eliminated [5]. Thus, these
compounds appear to induce functional antagonism via a non-
competitive mechanism. Short-acting k antagonists did not
activate JNK1 [6].
Transient effects
Surprisingly, despite the extremely protracted timecourse of k
antagonism, other effects of nor-BNI, GNTI and JDTic are of
rapid onset and brief duration [4,7]. After subcutaneous (s.c.)
administration to mice, nor-BNI and GNTI induce scratching that
is maximal within 20 minutes and lasts less than two hours [8,9].
Nor-BNI and JDTic inhibit self-administration of ethanol by rats
at 2 hours, but not 24 hours [10]. Nor-BNI also reduces the
maximal responding rate to intracranial self-stimulation in rats
over the first two hours, but not after 24 hours [11]. In mice,
GNTI strongly inhibits locomotor activity within 20 minutes, but
the effect dissipates within three hours [12]. Nor-BNI inhibits
locomotor activity in rats on the day of administration, but not the
next day [13]. Despite its high k-selectivity in vitro [3], nor-BNI
produces transient m and d antagonism in mice, again with rapid
onset and lasting only a few hours [14,15]. Thus, all three of these
compounds have transient effects.
Potential mechanisms of transient effects
These effects are maximal when k antagonism is submaximal
(,2 hours), and undetectable when antagonism is maximal
(24 hours) [4,16]. This strongly suggests that these effects are not
mediated by antagonism of the endogenous k opioid dynorphin A
(dynA). We recently found that nor-BNI, GNTI and JDTic are
rapidly absorbed and eliminated from plasma after intraperitoneal
(i.p.) administration, coinciding closely with the timecourse of their
transient effects [7]. We have argued that such effects are likely to
result from competitive, reversible mechanisms, while the delayed,
prolonged timecourse of k antagonism is more consistent with a
non-competitive, irreversible process such as desensitization [7].
While k antagonism cannot plausibly account for these transient
effects, the fact that some of them are caused by several of these
compounds suggests that they may nonetheless be k-OR-
mediated. They might, for instance, result from inverse or biased
agonism. However, effects seen after only one of these agents
suggest the involvement of targets other than k opioid receptors (k-
OR). Dramatically, we found that administration of a high dose of
GNTI to mice (30 mg/kg i.p.) caused ataxia, convulsions and
death within 18 minutes. By contrast, even at 100 mg/kg, nor-
BNI and JDTic caused no convulsions or deaths [7]. Naltrexone is
also much less toxic to mice (LD50 = 570 mg/kg s.c.) [17]. The
GNTI analogue 59-aminomethylnaltrindole was also recently
reported to induce gasping and convulsions after a high dose
(20 mg/kg i.p.), suggesting that this series of compounds may act
on a common target other than k-OR [18].
Nor-BNI [19], GNTI [20] and JDTic [21] all inhibit
deprivation-induced feeding in rats. Surprisingly, however, while
nor-BNI also inhibits feeding induced by butorphanol or
neuropeptide Y, GNTI does not [20]. These contrasting profiles
suggest that nor-BNI or GNTI, or both, interact with another
target that modulates feeding. Evidence has recently been
presented that GNTI-induced scratching is mediated by targets
other than k-OR [9,22–25]. In addition to the discrepancy in
timecourse noted above, scratching was not inhibited by naloxone,
Figure 1. Structures of opioid antagonists nor-BNI, GNTI, JDTic and naltrexone.
doi:10.1371/journal.pone.0070701.g001
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and was equally intense in k-OR knockout mice [9]. Screening of
1 mM GNTI against a panel of 34 non-opioid receptors and ion
channels revealed substantial binding only to M1 muscarinic
receptors (M1-R) [9]. In vivo, M1 agonist McN-A-343 inhibited
GNTI-induced scratching, consistent with the in vitro evidence for
the involvement of this receptor [9,25].
Less evidence is available on the affinities of nor-BNI and JDTic
for non-opioid targets. Nor-BNI has been reported to show very
low affinity (Ki.1 mM) for the N-methyl-D-aspartate (NMDA)
receptor [26], and to weakly modulate dynA binding to the same
receptor [27]. No binding was detected at 10 mM to the
glucocorticoid receptor NR3C1 [28]. Nor-BNI’s affinity for the
opioid-like nociceptin/orphanin FQ receptor (NOP) is also
negligible; one study found low affinity (Ki = 780 nM) [29], while
another detected no binding at 10 mM [30].
To summarize, the mechanisms underlying the transient effects
of nor-BNI, GNTI and JDTic are unknown, and differences
between these compounds suggest that non-opioid targets may be
involved. In this study, we sought evidence of such interactions.
Using the resources of the National Institute of Mental Health’s
Psychoactive Drug Screening Program [31], we measured the
binding affinities of nor-BNI, GNTI and JDTic for 46 receptors,
ion channels and neurotransmitter transporters, and evaluated hits
in functional assays. We also tested for active efflux from Caco-2
cell monolayers, which express multiple efflux transporters.
Results
Nor-BNI, GNTI and JDTic bind selectively to opioid
receptors
As expected, nor-BNI, GNTI and JDTic bound selectively to k-
over m- and d-OR, albeit with lower selectivity (3 to 44-fold) than
in some previous reports [3]. All three compounds had very low
affinities for non-opioid targets generally (Table 1): at most targets,
(26 of 43), none of the three compounds bound detectably at
10 mM. Furthermore, there was no non-opioid target to which all
three compounds bound detectably at 10 mM, or for which any
two shared sub-micromolar affinity. Only three sub-micromolar
affinities were detected: nor-BNI for the a2C-adrenoceptor (a2C-
AR, Ki = 630 nM), and JDTic for the opioid-like receptor NOP
(Ki = 12 nM) and the noradrenaline (norepinephrine) transporter
(NET, Ki = 54 nM).
Nor-BNI does not bind to NMDA receptors
Contrary to previous reports, we detected no binding by nor-
BNI to NMDA receptors. However, this receptor’s multiple
binding sites complicate comparisons. Nor-BNI was reported to
weakly displace 3H]CGP-39,653 from the glutamate site [26], and
to modulate displacement of [3H]-MDL-105,519 from the glycine
site by dynA [27]. In our hands, nor-BNI did not displace
[3H]MK-801 from the phencyclidine (cation channel) site at
10 mM,. This does not exclude the possibility of binding to the
glutamate and glycine sites. Note that in previous reports, binding
to these sites was only detectable at nor-BNI concentrations above
1 mM, consistent with the negligible affinity observed here.
GNTI is an allosteric enhancer of a1A-AR (EC50 = 41 nM)
In initial tests, GNTI showed affinity for a1A adrenoceptors
(a1A-AR). We therefore measured functional activity in an
intracellular calcium mobilization assay. Surprisingly, even at
30 mM GNTI neither activated a1A-AR nor inhibited activation
by noradrenaline (norepinephrine). To reconcile this apparent
discrepancy, we tested for allosteric enhancement of noradrena-
line’s effects.
In the calcium mobilization assay, GNTI did not activate a1A-
AR, but increased the maximal response to noradrenaline by up to
20% without affecting potency (Figure 2A). This suggests that
GNTI is an allosteric enhancer, or positive allosteric modulator.
The EC50 of GNTI for this enhancement was 41 nM (95%
CI= 24 to 72 nM). At the highest concentration of GNTI tested
(30 mM), the potency of noradrenaline and the increase in
maximal response were both reduced, suggesting that weak
competitive antagonism occurs at this concentration.
By contrast, GNTI slightly reduced the maximal response to
noradrenaline in an assay measuring hydrolysis of phosphatidy-
linositol 4,5-bisphosphate (PI); weak competitive antagonism again
occurred above 10 mM (Figure 2B). This discrepancy was
surprising, since PI hydrolysis leads to calcium mobilization.
However, other pathways governing a1A-AR-mediated calcium
mobilization reportedly exist [32]. While fluorescent dye-based
calcium assays of the kind we used can generate artefacts [33], the
lack of response to 30 mM GNTI in the absence of noradrenaline
argues against this (Figure 2A). These results suggest that GNTI
imposes functional selectivity on noradrenaline’s actions at a1A-
AR, selectively enhancing efficacy towards a PI-independent
signalling pathway.
Table 1. Binding affinities of nor-BNI, GNTI and JDTic for 46
neurotransmitter receptors and transporters, determined by
radioligand displacement.
nor-
BNI GNTI JDTic
nor-
BNI GNTI JDTic
Target Ki (nM) Target Ki (nM)
k 4 3 1 b3
m 41 54 3 D1
d 20 58 44 D2
NOP 4,400 2,500 12 D3
5-HT1a 1,100 D4
5-HT1b D5 3,900 8,200
5-HT1d 1,100 DAT 4,400
5-HT1e GABAA
5-HT2a GABAA (BZP)
5-HT2b H1
5-HT2c H2 1,800
5-HT3 H3
5-HT5a H4
5-HT6 M1
5-HT7 M2 5,400
a1D M3
a1A 9,800 M4
a1B 9,500 4,800 M5
a2A 4,900 NET 54
a2B 1,500 NMDA
a2C 630 2,200 SERT
b1 s1 1,900
b2 s2
Submicromolar affinities are shown in bold; blank cells indicate Ki$10 mM. For
details (uncertainty, radioligand, membrane type, species), see Table S1. For
binding curves, see File S1.
doi:10.1371/journal.pone.0070701.t001
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Upon retesting, we were unable to replicate our initial finding of
high binding affinity: GNTI displaced [125I]HEAT from a1A-AR
only at concentrations approaching 10 mM (Table 1). In addition,
10 mM GNTI did not detectably modulate the displacement of
[125I]HEAT by noradrenaline. This is not inconsistent with the
functional results, since allosteric modulators can affect efficacy
independently of affinity [34]. However, it is fortuitous that the
apparently incorrect initial result led us to investigate further.
To summarize, the above data indicate that GNTI acts as a
functionally-selective allosteric enhancer of a1A-ARs. Under these
conditions, GNTI increases maximal calcium mobilization by
noradrenaline, but does not enhance PI hydrolysis.
GNTI is a weak M1 antagonist (KB = 3.7 mM)
GNTI showed negligible affinity for all non-opioid targets
(Ki.2 mM). In a previous report [9], GNTI gave 52% displace-
ment from M1-R at 1 mM, while we observed only 49%
displacement at 10 mM. One potential reason for this small
difference is our use of a different radioligand, [3H]3-quinuclidinyl
benzilate (QNB); the previous report used [3H]N-methylscopola-
mine. Given the convergent evidence reported previously for the
involvement of M1-R [9], we nonetheless tested for functional
activity using an intracellular calcium mobilization assay
(Figure 3A). GNTI did not activate M1-R, and inhibited the
effect of acetylcholine with very low potency: KB = 3.7 mM (95%
CI= 3.2 to 4.3 mM). Given the consistently sub-nanomolar
potency of GNTI at k-OR in functional assays [3], these results
confirm .3,000-fold selectivity.
JDTic weakly inhibits noradrenaline transport
(IC50 = 1.1 mM)
JDTic bound to the noradrenaline transporter with moderately
high affinity (Ki = 54 nM versus [
3H]nisoxetine). However, in a
functional assay (Figure 3B), inhibition of transport only occurred
at much higher concentrations (IC50 = 1.1 mM, 95% CI=0.5 to
2.6 mM). This was not due to assay insensitivity, since the positive
control nisoxetine exhibited high potency (IC50 = 9 nM, 95%
CI= 5 to 15 nM). The surprisingly low potency of JDTic suggests
that it may bind with high affinity to an allosteric site, modulating
the affinity of [3H]nisoxetine without affecting noradrenaline
transport. Evidence for at least one affinity-modulating allosteric
site in NET has been reported previously [35]. The inhibition seen
at high concentrations may be due to JDTic binding with lower
affinity to a transport-modulating site.
JDTic weakly inhibits NOP (pA2,7.1)
JDTic bound with high affinity to NOP (Ki = 12 nM, 95%
CI= 7 to 20; Table 1), displacing the endogenous agonist
nociceptin/orphanin FQ ([3H]N/OFQ). Nor-BNI showed negli-
gible affinity, consistent with prior reports [29,30], as did GNTI.
Surprisingly, despite its high affinity and lack of efficacy, JDTic
only weakly inhibited the response to N/OFQ in a functional
assay (inhibition of cyclic AMP production: pA2= 7.1, 95%
CI= 5.9 to 8.3, Figure 4A). This would be equivalent to a KB of
73 nM for a competitive antagonist (95% CI= 4.6 to 1,200 nM).
Maximally-effective concentrations of N/OFQ (.100 nM) were
not affected even by extremely high concentrations of JDTic
(30 mM); this saturable effect suggests negative allosteric modula-
tion rather than competitive antagonism (Figure 4A). The full
displacement of [3H]N/OFQ we observed in the binding assay is
therefore surprising. Note, however, the low concentration of
[3H]N/OFQ used: 0.74 nM, equal to the Kd. At this concentra-
tion of N/OFQ, JDTic almost abolished response in the functional
assay (Figure 4A). The positive control SB-612,111 caused potent
surmountable antagonism, abolishing the response to maximally-
effective concentrations of N/OFQ (pA2= 9.8, 95% CI= 9.4 to
10.2, Figure 4B). This is concordant with a prior report [36]. The
extreme potency of JDTic in k-OR functional assays (Ke,20 pM)
[3] thus confers at least .1,000-fold selectivity over NOP and
NET, and the incomplete NOP antagonism we observed suggests
that effective selectivity is greater still.
Nor-BNI, GNTI and JDTic undergo active efflux from
Caco-2 cells
We next evaluated membrane permeation and active efflux,
measuring permeation through Caco-2 cell monolayers by UV
spectroscopy. Nor-BNI, GNTI, JDTic and naltrexone all ap-
peared to undergo active efflux, as indicated by an efflux ratio
greater than 1 (Table 2). Note, however, that compounds with
efflux ratios in this moderate range (,18) may be modulators
Figure 2. GNTI enhances maximal Ca2+ mobilization by noradrenaline at a1A-AR without affecting potency (A); maximal PI
hydrolysis is not increased (B). Some intermediate curves have been omitted for clarity. Error bars represent mean 6 S.E.M. For raw data, see
Datasets S1 and S2.
doi:10.1371/journal.pone.0070701.g002
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rather than substrates [37]. Contrary to these results, in previous
tests using Caco-2 and other cell lines, naltrexone was not found to
undergo active efflux [7,38,39]. The permeabilities we observed
for all four compounds were also orders of magnitude higher than
we previously observed in LLC-PK1 cell layers [7]. We are
unaware of the reason(s) for these discrepancies; Caco-2 cell
populations exhibit substantial heterogeneity, with differences in
the expression of particular transporters and high inter-laboratory
variation in permeation rates [40,41]. Nonetheless, the finding that
nor-BNI, GNTI and JDTic are subject to active efflux is consistent
with the low brain uptake we observed previously [7]. We found
there that nor-BNI and GNTI were not substrates of human
permeability glycoprotein (P-gp); taken together our results suggest
that these antagonists may be substrates of another efflux
transporter.
Discussion
Potential consequences of a1A-AR modulation by GNTI
Our results indicate that GNTI is a moderately potent allosteric
enhancer of a1A-AR. It is interesting to note that GNTI is
structurally similar to other a1-AR ligands (Figure 5). Aperidine
and analogues act as a1A-AR antagonists, and a guanidine
substituent is required for activity [42]. The peptide r-TIA (not
shown) is a negative allosteric modulator of a1-AR, also featuring a
guanidine substituent that is essential for activity [43].
Clonidine is an allosteric modulator of a1A-AR [44] featuring a
phenylimidazoline moiety similar to the phenylguanidine group of
GNTI (Figure 5). Clonidine and many related ligands appear to
bind in an allosteric pocket of the a-AR, unlike the orthosteric
phenethylamines [45]. The structurally-related sodium channel
blocker amiloride and analogues (Figure 5) are negative allosteric
Figure 3. GNTI is a weak antagonist of acetylcholine at M1-R (A); JDTic weakly inhibits the noradrenaline transporter (B). Error bars
represent mean 6 S.E.M. For raw data, see Datasets S3 and S4.
doi:10.1371/journal.pone.0070701.g003
Figure 4. Antagonism of N/OFQ at NOP by JDTic (A) and SB-612,111 (B): inhibition of cAMP production. Error bars represent mean 6
S.E.M. For raw data, see Dataset S5.
doi:10.1371/journal.pone.0070701.g004
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modulators of a1A-AR [46]. These prior results indicate that a1A-
AR possesses an allosteric site that binds structurally diverse
guanidine-substituted ligands and related compounds. Interesting-
ly, it has recently been reported that unlike the orthosteric agonist
noradrenaline, the imidazolines are functionally selective at a1A-
AR, with a bias towards calcium mobilization [47].
Allosteric enhancement of noradrenaline’s actions at a1A-AR
may plausibly contribute to some of GNTI’s transient effects. For
instance, a1 agonists have been reported to inhibit feeding [48]
and serotonin-induced itch [49]. The ataxia and death we
observed after high-dose GNTI [7] may also be related, since
a1-AR agonists have been found to promote catalepsy [50] and to
raise blood pressure [51]. Furthermore, GNTI’s potency as an a1A
enhancer (41 nM) is comparable to our estimate of the unbound
brain concentration after a high dose of GNTI (5 nM after
39 mg/kg) [7]. Thus, it is plausible that synergy between this
target and k-OR might contribute to centrally-mediated effects of
GNTI such as inhibition of feeding and locomotion. Such an
interaction is less plausible for M1-R, towards which the potency of
GNTI is orders of magnitude lower.
Do M1 receptors contribute to GNTI-induced scratching?
Remaining questions
Our finding that GNTI acts as a weak M1 antagonist is
consistent with a previous report of weak binding to that receptor
[9]. Nonetheless, it is unclear whether the extremely low potency
we observed would be relevant in vivo. In the prior report, an M1
agonist (McN-A-343) inhibited GNTI-induced scratching in mice,
providing apparent in vivo confirmation that GNTI acts upon this
receptor [9,25]. An M1 antagonist had no effect. However, those
results are difficult to interpret, for several reasons. Firstly, in
earlier reports M1 agonists induced scratching, while antagonists
inhibited it [52]. Thus, the reported inhibition of GNTI-induced
scratching by an M1 agonist is paradoxical. Secondly, McN-A-343
was administered intrathecally (i.t.), while GNTI was injected s.c.
[9]. Due to GNTI’s low potency and extremely low central uptake
[7], this would be unlikely to result in a detectable effect on spinal
M1-R. Indeed, GNTI induces scratching after s.c. but not i.t.
administration [9], while M1 agonists show the opposite profile
[53], suggesting that any interaction would be indirect. Finally,
McN-A-343 is poorly selective for M1 receptors [54], so the
involvement of other targets cannot be ruled out. Collectively, this
evidence is more consistent with an indirect, downstream
interaction than a competitive one between GNTI and McN-A-
343 at spinal M1 receptors. Further exploration of this issue would
benefit from the use of more selective M1 ligands, administered by
the same route as GNTI.
Potential roles of peripheral non-opioid targets in the
transient effects of nor-BNI and GNTI
It remains plausible that peripheral M1 receptors may be
involved in some transient effects of GNTI. We previously
observed peak unbound GNTI concentrations in plasma of
2 mM at a dose of 10 mg/kg, and 8 mM at 39 mg/kg [7]. These
concentrations would be expected to result in some peripheral M1
Table 2. Mean permeation rates and efflux ratios in Caco-2
cell monolayers.
Papp Efflux ratio
Compound BRA ARB
B?A
A?B
nm/s
Nor-BNI 3,100 510 6.1
GNTI 2,700 880 3.1
JDTic 3,100 600 5.2
Naltrexone 2,700 590 5.7
Data are the mean of three independent determinations (samples in triplicate)
each with SEM ,10%. A: apical; B: basolateral.
doi:10.1371/journal.pone.0070701.t002
Figure 5. Structural similarities between GNTI and a1-AR ligands.
doi:10.1371/journal.pone.0070701.g005
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antagonism, given KB= 3.7 mM. At these concentrations, detect-
able receptor occupancy would also be expected at five other
peripheral targets, including M2-R (Table 1). Similarly, the peak
unbound concentration of nor-BNI in plasma was 3 mM at
10 mg/kg [7], comparable to the affinities determined here for six
non-opioid targets. Thus, due to the very low uptake of nor-BNI
and GNTI, effective levels in brain require very high plasma
concentrations after peripheral administration. These concentra-
tions will result in transient occupancy of peripheral targets for
which these compounds have low affinity, reducing their effective
selectivity. The relevance of this in vivo is unclear. While it seems
plausible that peripheral receptors might influence responses such
as scratching, this seems less likely for behaviours such as
locomotion and feeding. The peak unbound concentration of
JDTic in plasma was 100 nM after a 10 mg/kg dose [7]. Based on
our results, this concentration would be expected to yield
substantial binding to NOP and NET, but little or no functional
effect. Moreover, this concentration would not be expected to
produce substantial occupancy of any of the other non-opioid
targets studied here.
Plasma concentrations of nor-BNI, GNTI and JDTic decline by
over 80% within 4 hours, and over 98% within 24 hours [7]. By
contrast, k opioid antagonism is maximal at 24 hours in each case
[4]. To achieve optimal selectivity, these compounds should
therefore be administered at least 4 and preferably 24 hours before
testing [4,14,15]. With an adequate pre-administration interval,
none of the non-opioid activities we report here are likely to be
detectable in vivo.
Is JDTic a negative allosteric modulator of NOP?
Surmountable but noncompetitive antagonism of the kind
exhibited by JDTic at NOP suggests allosteric modulation.
However, it seems unlikely that JDTic binds to an allosteric site.
JDTic protrudes deeply into the orthosteric site of k-OR in the
recently reported crystal structure [55]. C-24, a peptide mimetic
derived from nociceptin, adopts the same pose in the orthosteric
site of NOP, superimposable upon JDTic [56]. The binding
pockets of k-OR and NOP are extremely similar: dynA shows
nanomolar affinity for NOP, and subnanomolar affinity for point
mutants [29]. Therefore, the most plausible binding site for JDTic
in NOP is the common orthosteric site exhibited in the crystal
structures. This is puzzling given the apparent allosteric modula-
tion we observed. Note, however, that allosteric modulation can
occur between two orthosteric ligands bound to a receptor dimer
[57].
Conclusions
Our results confirm that nor-BNI, GNTI and JDTic bind with
high selectivity to the k-OR, extending previous results for opioid
receptors to a broad panel of 43 non-opioid receptors and
transporters. There was no non-opioid target for which all three
compounds shared detectable affinity, or for which any two shared
sub-micromolar affinity, while affinity for k-OR was low
nanomolar. Of the other interactions detected, the only one likely
to occur in the CNS at typical concentrations is allosteric
enhancement of a1A-AR by GNTI. This may partially account
for that compound’s severe transient effects. However, due to the
low brain uptake of these compounds, achievement of effective
central concentrations requires high plasma levels, which may
briefly influence low-affinity peripheral receptors. For instance,
GNTI acted as a weak M1 antagonist. Nonetheless, the k opioid
antagonism these compounds induce persists for weeks or months
after these transient effects dissipate. With an adequate pre-
administration interval, our results confirm that nor-BNI, GNTI
and JDTic are exquisitely selective tools for the study of k-OR in
vivo.
Materials and Methods
Compounds
GNTIN2HClN1.5H2O: Tocris Bioscience, Ellisville MI (batches
4B/91591 and 4B/94133). JDTicN2HClNH2O: F. Ivy Carroll,
Research Triangle Institute, NC. NaltrexoneNHClN2H2O: Tocris
Bioscience (batch 5B/93329). Nor-BNIN2HClNH2O: Tocris Bio-
science (batches 8A/90732 and 9A/93084). Other compounds
were purchased from Sigma-Aldrich (Milan, Italy).
Binding and functional assays
Inhibition of the noradrenaline transporter (NET) was
determined using fluorescent dye uptake (Neurotransmitter
Transporter Uptake Assay Kit R8174, Molecular Devices,
Sunnyvale CA) [58]. NOP binding assays were performed against
[3H]N/OFQ in membranes prepared from HEK293T cells
transiently transfected with human NOP as described previously
[56]. Cyclic AMP inhibition by N/OFQ was determined in the
same cells using a GloSensorTM assay (Promega Corp., Madison
WI) as described elsewhere [59]. Briefly, cells were preincubated
with antagonist for 15 min, then agonist for 15 min, before
addition of luciferin and isoproterenol. Luminescence was
measured after a further 20 minutes. Other functional and
radioligand displacement assays were performed using standard
PDSP protocols as described previously [60]. For all binding and
functional assays, a minimum of three experiments were
conducted in triplicate. For details of specific binding assays,
see Table S1. Results were analyzed using nonlinear regression
with Graphpad Prism 6.
Caco-2 cell monolayer permeation
Caco-2 cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% heat-inactivated fetal calf serum, 100 U/mL
penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine. The
cells were trypsinized twice a week with trypsin/ethylenediamine-
tetraacetic acid (EDTA) (0.02% each) and the medium was
changed twice a week. Cells were harvested with trypsin-EDTA
and seeded onto a MultiScreen Caco-2 assay system (Millipore,
Billerica, MA) at a density of 10,000 cells per well. The culture
medium was replaced every 48 h for the first 6 days and every
24 h thereafter, and after 21 days in culture, the Caco-2
monolayer was utilized for the permeability experiments. Trans-
epithelial electrical resistance (TEER) of the monolayers was
measured daily before and after the experiment using an epithelial
volt-ohm meter (Millicell-ERS; Millipore, Billerica, MA). TEER
values were greater than 1800 V for 21-day cultures.
Apical to basolateral (Papp, ARB) and basolateral to apical
(Papp, BRA) permeability of compounds were measured at
120 min and at various compound concentrations (1–100 mM).
Compounds were dissolved in Hanks’ balanced salt solution
(HBSS, pH 7.4) and sterile filtered. After 21 days of cell growth,
the medium was removed from filter wells and from the receiver
plate. The filter wells were filled with 75 mL of fresh HBSS buffer
and the receiver plate with 250 mL per well of the same buffer.
This procedure was repeated twice, and the plates were incubated
at 37uC for 30 min. After incubation time, the HBSS buffer was
removed and compound solutions added to the filter well (75 mL).
HBSS without the compound was added to the receiver plate
(250 mL). The plates were incubated at 37uC for 120 min. After
incubation time, samples were removed from the apical (filter well)
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and basolateral (receiver plate) side of the monolayer and then
were stored in a freezer (220uC) pending analysis. Concentrations
were calculated from UV absorbance at the following wavelengths
(nm): 278 (nor-BNI); 285 (GNTI); 276 (JDTic); 228 (naltrexone).
The apparent permeability (Papp), in nm sec
21, was calculated
using the following equation:
Papp~
VA
Area|time
 
|
drug½ acceptor
drug½ initial
 
where VA is the volume (in mL) in the acceptor well; Area is the
surface area of the membrane (0.11 cm2 of the well); time is the
total transport time in seconds (7200 s); [compound]acceptor is the
concentration of the compound measured by UV spectroscopy;
[compound]initial is the initial compound concentration in the
apical or basolateral wells.
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